CytomX Therapeutics
CTMX
62 hedge funds and large institutions have $41.8M invested in CytomX Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 8 closing their positions.
1,425% more call options, than puts
Call options by funds: $61K | Put options by funds: $4K
2.92% less ownership
Funds ownership: 51.43% → 48.52% (-2.9%)
7% less funds holding
Funds holding: 67 → 62 (-5)
29% less capital invested
Capital invested by funds: $58.7M → $41.8M (-$16.9M)
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$370K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$211K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$80.8K |
| 4 |
Millennium Management
New York
|
+$78.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$50.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$896K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$592K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$467K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$381K |
| 5 |
Renaissance Technologies
New York
|
-$303K |
CTMX Hedge Fund Activity: Q3 2023 in Review
62 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2023, worth a combined $41.8M — down 29% from $58.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CTMX and 3 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was Bank of New York Mellon, adding an estimated $370K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $896K.
- 62 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2023, down from 67 in Q2 2023.
- Funds reported $41.8M of CytomX Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 3 funds opened new CytomX Therapeutics positions in Q3 2023 and 8 closed out, a net change of -5 holders.
- The largest CytomX Therapeutics buyer in Q3 2023 was Bank of New York Mellon, an estimated $370K added.
- The largest CytomX Therapeutics seller in Q3 2023 was Jacobs Levy Equity Management, an estimated $896K sold.
Based on aggregated 13F filings for Q3 2023.